One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The historical renal cutoff is preserved. Current product labeling and professional recommendations may use different thresholds; do not silently reconcile them.
The label retains a CrCl-below-60 contraindication; the AGS 2023 older-adult criterion uses below 30. This difference does not establish safety for every patient between those values.
What to reconcile: Confirm population, lower-tract indication, duration and local policy. Document any departure from labeling; neither a source count nor this comparison selects a prescription.
Open this note and its source referencesThe added historical MHRA advice differs in renal measure, cutoff and limited lower-UTI exception from the retained U.S. label and geriatric/institutional sources. It is not a new 2026 U.S. rule.
What to reconcile: Keep jurisdiction, infection site, source date and renal estimator attached to each recommendation. Do not substitute one numerical cutoff for another without clinical adjudication.
Open this note and its source referencesThe label restriction, UCSF limited-data position and UK short-course exception differ in renal measure, setting and qualifications. UCSF is not an endorsement down to CrCl 30.
What to reconcile: Document jurisdiction and infection scope; preserve the UK multidrug-resistant lower-UTI and benefit-risk qualifications. Do not convert eGFR thresholds into CrCl cutoffs.
Open this note and its source referencesThe retrieved MACROBID label lists anuria, oliguria and significant renal impairment, including CrCl <60 mL/min or clinically significant serum-creatinine elevation, as contraindications. Renal impairment also increases neuropathy concern; monitor renal function during long-term therapy. Keep this label position distinct from professional or non-US guidance with different thresholds. A toxicity warning is not a validated reduced-dose strategy.
RDM48-rxlist-nitrofurantoin-bc3599c9be-C1 · Source locator: Contraindications; neuropathy and geriatric renal warnings.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=nitrofurantoin&s1=RDM48-rxlist-nitrofurantoin-bc3599c9be&h1=600e28d6cf3109cc95bc6bc8b76ea894a0ae4c0c638e8b4093c72ecdb28d6d7a